TITLE:
Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma
AUTHORS:
Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova
KEYWORDS:
Anaplastic Large Cell Lymphoma, Relapse, Brentuximab Vedotin, Donor Lymphocyte Infusion, Minimal Residual Disease
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.8,
July
28,
2017
ABSTRACT: Minimal
residual disease (MRD) appears to have a strong negative predictive value for
disease recurrence in children with anaplastic large cell lymphoma (ALCL).
Brentuximab vedotin (BV) can be a therapeutic option for MRD-positive
patients to achieve molecular remission and to decrease risk of subsequent
relapse. We here report a 4-year-old child with ALCL progression during relapse
treatment who received BV as a bridging therapy before haploidentical
hematopoietic stem-cell transplantation, and as a maintenance therapy
post-transplant alone or combined with simultaneous low dose donor-lymphocyte
infusions. MRD monitoring showed a complete molecular response and reflected
both BV efficiency and graft-versus-lymphoma effect.